Outcome of children with CD19⁺ALAL and CD19⁻ALAL with other lymphoid-specific antigens by the type of primary therapy. Patients without ETV6/RUNX1, RUNX1/RUNX1T1, PML/RARA, or BCR/ABL1 gene fusions. A log-rank (Mantel-Cox) statistical test was used. (A) EFS of CD19⁺ ALAL. (B) EFS of CD 19⁻ ALAL with other lymphoid-specific antigens. (C) Overall survival of CD19⁺ patients. (D) Overall survival of CD19⁻ ALAL with other lymphoid-specific antigens. Other lymphoid-specific antigens are listed in “Results.”